Osteosarcoma is the most common primary bone malignancy in children and adolescents, accounting for approximately 2.4% of all malignancies in pediatric patients [1]. Because of its high propensity for distant metastasis, osteosarcoma is one of the leading causes of cancer-related death in adolescents. Metastasis, a major cause of
treatment failure in cancer, involves many complex processes such as cell migration, angiogenesis, adhesion, and proliferation [2]. Although osteosarcoma patients may initially respond to chemotherapy, those with metastatic or recurrent disease have extremely poor survival rates [3–5]. It is therefore critical to identify the mechanisms underlying osteosarcoma development and progression.

Collapsin response mediator proteins (CRMPs) comprise five isoforms (CRMP 1–5), all of which are highly expressed in developing neurons [6–8]. DRP5 (CRMP5), which was first identified as a CRMP-associated protein and designated as CRAM, shares the lowest homology with other CRMPs [9]. Accordingly, DRP5 regulates the dynamics of filopodia, growth cone development, dendritic development, and synaptic plasticity [10, 11] by interacting with other proteins such as Fes/Fps tyrosine kinase [12] and the mitochondrial protein septin [13]. Because of their involvement in regulating cell migration by interacting with the cytoskeleton [14–16], CRMP family proteins have generated interest in recent years for their potential role in cancer. The expression of the long form of CRMP-1, LCRMP-1, in patients with nonsmall-cell lung cancer (NSCLC) [17] and gastric cancer [18] was associated with poor clinical outcomes [19]. CRMP-2 was identified as a prognostic marker and candidate therapeutic target in NSCLC [20]. Reduced CRMP-2 expression and elevated expression of nuclear phosphorylated CRMP-2 were associated with breast cancer progression [21]. A neuronal autoantibody specific for DRP5 was identified and suggested as a marker of lung cancer and thymoma-related autoimmunity [22]. However, the role of DRP5 in osteosarcoma remains largely unknown. The high propensity of osteosarcoma to metastasize to the lung and the involvement of DRP5 in lung cancer underscore the need to investigate the potential role of DRP5 in the development of osteosarcoma. Here, we examined the expression of DRP5 in samples from osteosarcoma patients and cultured cells in vitro and in a mouse model in vivo.

Methods and Materials

Ethics statement

All human and animal experiments were approved by the Medical Ethical Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-Sen University. All experiments using human specimens were performed in accordance with the Declaration of Helsinki. Tissue samples were obtained from osteosarcoma patients in the First Affiliated Hospital of Sun Yat-Sen University. Informed consent was obtained from all participants prior to the study. All animal procedures were performed following the humane care guidelines of the Chinese National Institute of Health, and the protocols were approved by the committee of Sun Yat-Sen University (Approval Number: 2016[148]).

Cell culture and shRNA stable cell line

Human hFOB1.19 osteoblasts and the osteosarcoma cell lines SAOS2 and MG63 were purchased from Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco’s minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), streptomycin (100 μg/mL), and penicillin (100 U/mL) in a humidified atmosphere with 5% CO₂ at 37°C. The pLKO.1 puromycin vector (Addgene, Cambridge, MA) with a U6 promoter was used for the construction of recombinant lentiviral plasmid encoding sh-DRP5. The shRNA sequence was as follows: 5′-GTGGACGCTTATGAGAAGT-3′. HEK 293T cells were cotransfected with pLKO.1 puromycin and packaging vectors. The supernatant was harvested at 48 and 72 h after transfection. MG63 cells were infected with shDRP5 and shCtrl (negative control, NC) in the presence of 5–10 μg/mL polybrene; after 48 h, cells were incubated in medium with 2 μg/mL puromycin for 12 days to generate osteosarcoma-MG63 shDRP5 stable cell lines.

In vivo tumor model

Animal experiments were performed under approval from the Committee on Animal Research of Sun Yat-Sen University, Guangzhou. To investigate the effect of DRP5 inhibition on osteosarcoma cell growth in vivo, cells (2 × 10⁶) from the osteosarcoma MG63-shDRP5 and MG63-shCtrl stable lines were inoculated subcutaneously into the flanks of nude mice. Six mice (one mouse in the shDRP5 group died) were included in each group; tumors were measured during the study period, and tumor volume was calculated using the formula for a prolate spheroid (V = 4/3 πa²b) [23]. Four weeks later, mice were sacrificed, and tumor weight was recorded.

Migration and invasion assay

Cell migration assays were performed using a Transwell system (Millipore, MA). Cells were cultured in serum-free DMEM for 24 h, trypsinized, and resuspended in serum-free DMEM. Cells were seeded in the upper chamber of the Transwell insert and incubated with 0.5% DMSO or deguelin (10 and 15 μmol/L), and 90% DMEM containing 10% FBS was added to the lower chamber and incubated for 48 h. The remaining cells in the upper chamber were removed. Cells migrated into the lower surface of the filter were fixed and stained with 2% crystal violet for quantification. For the invasion assay, the Transwell filter
membrane was coated with Matrigel (Becton Dickinson Bioscience, MA). Cell numbers were expressed as the mean ± SD. At least three experiments were performed and each was performed in triplicate.

**MTS assay**

In vitro cell proliferation was assessed with the CellTiter 96® AQueous One Solution Cell Proliferation Assay Kit (Promega, Madison, WI) according to the manufacturer's instructions. In brief, in each group, cells were allowed to grow for 6, 24, 48, and 72 h. At harvesting, 20 μL of CellTiter 96 AQueous One Solution reagent was added to each well in a total volume of 100 μL of medium and incubated for 3–4 h. Absorbance was measured at 490 nm using an ELISA plate reader. The growth rate was calculated from the absorbance, and the readings at 6 h time points in each group were set to 100%.

**Cell cycle assay by flow cytometry**

Cells plated in six-well plates were washed twice with PBS and fixed in 70% ethanol at 4°C overnight. Then, cells were incubated with propidium iodide at room temperature for 1 h and analyzed by flow cytometry using a FACScan flow cytometer (BD Biosciences, Mountain View, CA).

**Wound healing assay**

MG63 cells were grown in six-well dishes until confluence. The confluent monolayer was scraped with a pipette tip. Then, the cells were washed twice with PBS and cultured in a 5% CO₂ incubator for 48 h at 37°C. Images of each well were acquired immediately and at 24 and 48 h in four random fields using an inverted fluorescence microscope (Nikon Corporation, Tokyo, Japan) at ×100 magnification. Wound closure was expressed as the average ± SEM of the difference between the measurements at time zero and the 24–48 h time period.

**Immunohistochemistry**

The specific anti-DRP5 antibody for western blotting and immunohistochemistry was purchased from Abcam (Cambridge, MA). For immunohistochemistry, paraffin sections were treated with hydrogen peroxide to inactivate endogenous peroxidases. Antigen retrieval was performed in a microwave in 10 mmol/L citrate buffer at pH 6.0. Sections were fixed with paraformaldehyde followed by permeabilization and blocking. Sections were then incubated in anti-DRP5 antibody overnight at 4°C, and a secondary antibody was used to detect protein expression. Immunostaining was analyzed with the Super Sensitive Non-Biotin Polymer HRP Detection System according to the manufacturer's instructions (BioGenex, San Ramon, Canada).

**Western blotting**

Cells were lysed in sample buffer and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described previously [24]. Primary antibodies against DRP5, matrix metalloproteinase (MMP)-2, and MMP-9 were obtained from Abcam. GAPDH (Abcam) was used as the loading control. After washing with PBS containing 0.1% Tween-20 five times, the membrane was incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences, Uppsala, Sweden) for 1 h, and bands were detected by enhanced chemiluminescence (Amersham). In all cases, the background intensities were first subtracted. Densitometric values were normalized to GAPDH levels.

**Total RNA extraction and RT-PCR**

Total RNA was isolated using the Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol, and the mRNA levels of DRP5 were evaluated by RT-PCR. First, RNA was reverse transcribed using RT-PCR Quick Master Mix (Toyobo Biochemicals, Osaka, Japan) according to the manufacturer’s protocol. The results were normalized to the expression of GAPDH. The oligonucleotide primers used were as follows: DRP5-forward, 5’- TTGTGGACGCTTATGAGAAGTG-3’; DRP5-reverse, 5’- CTCAC CAGTGTCCTCCATTTCCTG-3’; GAPDH-forward, 5’- GAG TCAAACGGATTGTGCTCTC-3’; GAPDH-reverse, 5’- GAC AAGCTTCCGTGTTCTCAG-3’.

**Statistical analysis**

All experiments were repeated at least three times, and the results are presented as the mean ± SD. Analyses of
significance were performed using Student's t-tests or one-way ANOVAs, followed by Bonferroni corrections. ROC curve analysis was used to define the cutoff score for high expression of DRP5. Survival curves were built using the Kaplan–Meier method and analyzed using the log-rank test. SPSS 20.0 software was used for statistical analyses. A value of \( P < 0.05 \) is considered statistically significant.

**Results**

**DRP5 is upregulated in human osteosarcoma cell lines**

To evaluate the role of DRP5 in osteosarcoma, the mRNA and protein expression levels of DRP5 were measured by western blotting and RT-PCR in hFOB1.19.
osteoblasts and the osteosarcoma cell lines SAOS2 and MG63. DRP5 mRNA levels were higher in osteosarcoma cell lines than in the osteoblast hFOB1.19 line (Fig. 1A). DRP5 mRNA levels normalized to GAPDH expression are shown in Figure 1B. Assessment of protein levels showed a similar pattern to that of mRNA levels (Fig. 1C and D). These results indicated that DRP5 is significantly overexpressed in osteosarcoma, suggesting the

Figure 2. Reduced cell growth in DRP5 knockdown cells. (A, B) The protein levels of DRP5 and the invasive factors MMP-2 and MMP-9 were detected in shRNA stable cell lines. Data normalized to GAPDH are shown (B). (C) Representative wound healing assays and (D) analysis of growth rates are shown. All experiments were performed in triplicate, and results are expressed as the mean ± SD. * denotes P < 0.05 versus normal cells. # denotes P < 0.05 versus shCtrl cells.
involvement of DRP5 in osteosarcoma development. To better understand the potential function of DRP5 in osteosarcoma cells, migration and invasion assays were performed in hFOB1.19, SAOS2, and MG63 cells. As shown in Figure 1E and F, the number of migrated and invaded cells was greater in osteosarcoma cell lines than in the normal osteoblast cell line. This increased migration and invasion capacity was consistent with the upregulation of DRP5 in osteosarcoma cell lines.

**Figure 3.** Reduced cell migration and invasion in DRP5 knockdown cells. Normal, shCtrl, and shDRP5 MG63 cells were subjected to migration (A), invasion (B), and flow cytometry (C) assays. All experiments were performed in triplicate, and results are expressed as the mean ± SD. * denotes P < 0.05 versus normal cells. # denotes P < 0.05 versus shCtrl cells.

**DRP5 silencing suppressed migration and invasion of osteosarcoma cells**

Because MG63 showed the highest migration and invasion activity, we chose this cell line to establish a stable DRP5 knockdown cell line (shDRP5) to further analyze the role of DRP5 in osteosarcoma development. A DRP5 shRNA lentivirus was designed, and the scrambled sequence was used as the NC (shCtrl). After successful generation of the two stable cell lines, protein expression was assessed by western blotting. DRP5 expression was significantly
downregulated in osteosarcoma shDRP5 cells, indicating the efficient knockdown effect (Fig. 2A and B). DRP5 silencing was associated with the downregulation of MMP-2 and MMP-9, two commonly used markers of migration and invasion (Fig. 2A and B). Next, cell migration was assessed by the wound healing assay and growth rate by the MTS assay. Wounds generated on shDRP5 MG63 osteosarcoma cells did not heal for 48 h, at which time wounds in the shCtrl cells were almost completely healed (Fig. 2C and D). In addition, DRP5 knockdown significantly inhibited the migration and invasion of MG63 cells compared with those of normal and shCtrl control cells (Fig. 3A–D). The effect of DRP5 knockdown on cell cycle progression was assessed by flow cytometry. DRP5 knockdown induced cell cycle arrest at G0/G1 phase (Fig. 3E–F). Taken together, these data suggested that DRP5 is involved in osteosarcoma development and plays a critical role in the migration and invasion of osteosarcoma cells in vitro.

**DRP5 silencing suppressed the growth of osteosarcoma cells in vivo**

Next, we investigated whether DRP5 inhibition affected tumor cell growth in an osteosarcoma orthotopic animal model in vivo. shDRP5 MG63 and shCtrl MG63 cells were inoculated subcutaneously into the flanks of nude mice. Tumor-bearing mice were sacrificed on day 30, and
assessment of tumors showed that DRP5 knockdown significantly suppressed tumor growth compared with that in control mice (Fig. 3A and B). The tumor weight (Fig. 4C) and tumor volume (Fig. 4D) were markedly decreased in shDRP5 mice compared with those in the control group. Taken together, these data indicated that DRP5 is involved in osteosarcoma development, and inhibition of DRP5 can suppress tumor cell growth of osteosarcoma in vitro and in vivo.

**High DRP5 protein expression is associated with poor clinical outcomes in patients with osteosarcoma**

Because our results suggested that DRP5 acts as an oncoprotein in osteosarcoma, the clinical significance of DRP5 was evaluated in primary human osteosarcoma tissue samples. Surgical specimens from 108 cases of osteosarcoma collected between January 2005 and December 2009 were immunohistochemically stained for DRP5 (Table 1). As shown in Figure 4A, the DRP5 protein localized to the nucleus and cytosol of cancer cells. The correlations between DRP5 expression and the clinical characteristics of patients are presented in Table 2. Because osteosarcoma has a high rate of lung metastasis [25, 26], we collected data on lung metastasis in osteosarcoma patients. The ROC curves for DRP5 showed the point on the curve closest to 0.0 and 1.0, which maximized both the sensitivity and specificity for overall survival (Fig. 5B) and lung metastasis (Fig. 5C). Osteosarcoma patients with high DRP5 protein expression had a significantly shorter overall survival time (Fig. 5D) and lung metastasis-free survival time (Fig. 5E) than those with low DRP5 expression. These data suggest that high DRP5 protein expression is associated with poor clinical outcomes in patients with osteosarcoma.

**Discussion**

Osteosarcoma is the most common primary malignant tumor of the bone and is associated with a high rate of pulmonary metastasis, which is the most critical prognostic factor for survival. Approximately, 15–25% of osteosarcoma patients develop metastatic disease, leading to failure of treatment. The 5-year survival rate of patients with metastasis from osteosarcoma is approximately 10–20%, whereas the survival rate is 60–70% in patients without metastasis [27, 28]. However, the underlying molecular mechanisms remain largely unknown. The identification of novel proteins involved in osteosarcoma development has potential applications in anticancer treatment. To elucidate the mechanism underlying the progression of human osteosarcoma, we collected specimens from osteosarcoma patients and used osteosarcoma cell lines to evaluate the role of

| Table 1. Clinical characteristics of 113 osteosarcoma patients |
|---------------------------------|
| **Total = 108** | **Percentage (%)** |
| **Age (years)** |
| Average | 19 |
| Range | 6–51 |
| **Gender** |
| Male | 69 | 63.8 |
| Female | 39 | 36.2 |
| **Location** |
| Distal femur | 59 | 54.6 |
| Proximal tibia | 25 | 23.1 |
| Proximal humerus | 12 | 11.1 |
| Proximal femur | 5 | 4.6 |
| Other | 7 | 6.5 |
| **Enneking score** |
| IIB | 82 | 75.9 |
| III | 26 | 24.1 |
| **Relapse** |
| Yes | 9 | 8.3 |
| No | 99 | 91.7 |
| **Lung metastasis** |
| Yes | 58 | 53.7 |
| No | 50 | 46.3 |
| **Death** |
| Yes | 55 | 50.9 |
| No | 53 | 49.1 |

| Table 2. The association of DRP5 expression with patient clinicopathological characteristics in 108 osteosarcoma tissues |
|---------------------------------|
| DRP5 expression level | Number | High | Low | **P value** |
| **Age** |
| ≤20 | 78 | 33 | 45 | 0.865 |
| 21–40 | 27 | 14 | 13 |
| >40 | 3 | 2 | 1 |
| **Gender** |
| Male | 69 | 33 | 37 | 0.245 |
| Female | 39 | 24 | 15 |
| **Location** |
| Distal femur | 59 | 36 | 23 | 0.634 |
| Proximal tibia | 25 | 12 | 13 |
| Proximal humerus | 12 | 5 | 7 |
| Proximal femur | 5 | 2 | 3 |
| Other | 7 | 4 | 3 |
| **Enneking score** |
| IIB | 82 | 38 | 44 | 0.741 |
| III | 26 | 15 | 11 |
| **Relapse** |
| Yes | 9 | 5 | 4 | 0.635 |
| No | 99 | 51 | 48 |
| **Lung metastasis** |
| Yes | 58 | 33 | 25 | 0.021 |
| No | 50 | 29 | 31 |
| **Death metastasis** |
| Yes | 55 | 29 | 26 | 0.006 |
| No | 53 | 23 | 30 |

*Chi-square test.*
DRP5 for the first time. Our results showed that DRP5 was significantly overexpressed at the mRNA and protein levels in osteosarcoma cell lines, and this upregulation was related to the migration and invasion activities of osteosarcoma cells. Knockdown of DRP5 markedly suppressed the expression of MMPs and inhibited the migration and invasion of osteosarcoma cells. Moreover, DRP5 silencing inhibited tumor growth in nude mice in vivo. DRP5 protein expression was high in patients with osteosarcoma and associated with significantly shorter overall survival and shorter lung metastasis-free survival rates than those of patients with low DRP5 levels. These data suggested the important role of DRP5 in osteosarcoma development and its potential role in osteosarcoma metastasis.

CRMPs are highly expressed in the developing and adult nervous system [6–8] and function in the regulation of neurite outgrowth and development, axonal guidance, and neuronal polarity and development. All CRMP proteins (CRMP 1–5) associate with the cytoskeleton [15, 29] to promote the migration of filopodia and lamellipodia, which is important for cancer metastasis and invasion [30]. In recent years, CRMP proteins have been implicated in the pathologies of a variety of human cancers. CRMP-1 is suggested to be a cancer suppressor [17, 31, 32], while
LCRMP-1 functions to promote cancer metastasis [19, 33, 34]. CRMP-2 was suggested as a prognostic marker and candidate therapeutic target in NSCLC and colorectal carcinoma [20, 35–37]. Regarding DRP5, its neuronal autoantibody was reported to be related with patients at risk for lung carcinoma [22, 38, 39]. The function of other CRMP proteins in cancer development remains to be elucidated. Although evidence of the role of CRMP proteins in cancer is accumulating, the underlying mechanisms need to be further explored.

MMPs are involved in epithelial–mesenchymal transition and in extracellular matrix degradation [40]. In the current study, knockdown of DRP5 resulted in a remarkable downregulation of MMP-2 and MMP-9, which was consistent with the reduced numbers of osteosarcoma cells with migratory and invasive activities. These results suggested that DRP5 functions upstream of MMPs to regulate the migration and invasion of osteosarcoma cells. The interaction of DRP5 with the cytoskeleton suggests that investigation of the relationship between DRP5 and tubulin and actin during osteosarcoma development is warranted. CRMP proteins are regulated by a variety of posttranscriptional modifications. They can be phosphorylated by many kinases, most notably GSK-3β [41], cyclin-dependent kinase 5 (Cdk5) [42], and Rho-associated kinase [43]. All members of the CRMP family, including DRP5, contain a Cdk5 phosphorylation consensus site. Thr514 phosphorylated CRMP-2 in samples obtained from patients with localized NSCLC was shown to regulate the mitosis of cancer cells, and CRMP-2 phosphorylation was suggested as a prognostic marker [20]. The functions of the upstream kinases of DRP5 and the phosphorylation status during osteosarcoma progression remain to be explored, which is worth investigating in future studies.

In conclusion, the present study describes the relevance of DRP5 during osteosarcoma development. DRP5 was upregulated in osteosarcoma specimens and cell lines and shown to function via the downstream MMPs. Inhibition of DRP5 suppressed the growth of cancer cells in vitro and in vivo, and high expression levels of DRP5 were associated with poor prognosis in osteosarcoma patients. These data suggested that DRP5 is a prognostic marker and potential new target for cancer therapy.

Acknowledgments

This work was supported by grants from National Natural Science Foundation of China (no. 81102040, no. 81372866), Guangdong Natural Science Foundation (2013010016847), Pharmaceutical Health Science and Technology General Guide Project of Guangzhou (2014A0101022), and Young teachers cultivating project of Sun Yat-Sen University (no. 14ykpy16).

Conflict of Interest

The authors declare no conflicts of interest.

References

1. Ta, H. T., C. R. Dass, P. F. Choong, and D. E. Dunstan. 2009. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 28:247–263.
2. Steeg, P. S. 2006. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12:895–904.
3. Barresi, V., S. Cerasoli, F. Morigi, A. M. Cremonini, M. Volpini, and G. Tuccari. 2006. Gliosarcoma with features of osteoblastic osteosarcoma: a review. Arch. Pathol. Lab. Med. 130:1208–1211.
4. Bramer, J. A., J. H. van Linge, R. J. Grimer, and R. J. Scholten. 2009. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur. J. Surg. Oncol. 35:1030–1036.
5. Broadhead, M. L., J. C. Clark, D. E. Myers, C. R. Dass, and P. F. Choong. 2011. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011:59248.
6. Minturn, J. E., H. J. Fryer, D. H. Geschwind, and S. Buck. 1995. TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth. J. Neurosci. 15:675–6766.
7. Fukada, M., I. Watakabe, J. Yuasa-Kawada, H. Kawachi, A. Kuroiwa, Y. Matsuda, et al. 2000. Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J. Biol. Chem. 275:37957–37965.
8. Yuasa-Kawada, J., R. Suzuki, F. Kano, T. Ohkawara, M. Murata, and M. Noda. 2003. Axonal morphogenesis controlled by antagonistic roles of two CRMP subtypes in microtubule organization. Eur. J. Neurosci. 17:2329–2343.
9. Inatome, R., T. Tsujimura, T. Hitomi, N. Mitsui, P. Hermann, S. Kuroda, et al. 2000. Identification of CRAM, a novel unc-33 gene family protein that associates with CRMP3 and protein-tyrosine kinase(s) in the developing rat brain. J. Biol. Chem. 275:27291–27302.
10. Hotta, A., R. Inatome, J. Yuasa-Kawada, Q. Qin, H. Yamamura, and S. Yanagi. 2005. Critical role of collapsin response mediator protein-associated molecule CRAM for filopodia and growth cone development in neurons. Mol. Biol. Cell 16:32–39.
11. Yamashita, N., B. Mosinger, A. Roy, M. Miyazaki, K. Ugajin, F. Nakamura, et al. 2011. CRMP5 (collapsin response mediator protein 5) regulates dendritic development and synaptic plasticity in the cerebellar Purkinje cells. J. Neurosci. 31:1773–1779.
12. Mitsui, N., R. Inatome, S. Takahashi, Y. Goshima, H. Yamamura, and S. Yanagi. 2002. Involvement of Fes/
Fps tyrosine kinase in semaphorin3A signaling. EMBO J. 21:3274–3285.
13. Takahashi, S., R. Inatome, H. Yamamura, and S. Yanagi. 2003. Isolation and expression of a novel mitochondrial septin that interacts with CRMP/CRAM in the developing neurones. Genes Cells 8:81–93.
14. Kimura, T., N. Arimura, Y. Fukata, H. Watanabe, A. Iwamatsu, and K. Kaibuchi. 2005. Tubulin and CRMP-2 complex is transported via Kinesin-1. J. Neurochem. 93:1371–1382.
15. Fukata, Y., T. J. Itoh, T. Kimura, C. Menager, N. Ichimori, T. Shiromizu, et al. 2002. CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat. Cell Biol. 4:583–591.
16. Tan, M. H., C. H. Cha, Y. H. Ye, J. F. Zhang, S. M. Li, F. M. Wu, et al. 2015. CRMP4 and CRMP2 Interact to Coordinate Cytoskeleton Dynamics, Regulating Growth Cone Development and Axon Elongation. Neuronal. 2015:947423. doi: 10.1155/2015/947423.
17. Shih, J. Y., S. C. Yang, T. M. Hong, A. Yuan, J. J. Chen, C. J. Yu, et al. 2001. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J. Natl Cancer Inst. 93:1392–1400.
18. Gumus, M., N. Yasar, S. Kayahan, S. Yuksel, O. Balvan, A. G. Mert, et al. 2013. The relationship between collapsin response mediator protein-1 (CRMP-1) expression and histopathologic parameters and survival in patient with gastric cancer. J. Clin. Oncol. 31:e15100.
19. Pan, S. H., Y. C. Chao, P. F. Hung, H. Y. Chen, S. C. Yang, Y. L. Chang, et al. 2011. The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. J Clin Invest. 121:3189–3205.
20. Olie, E., R. Pelaez, S. Garasa, M. J. Pajares, J. Agorreta, R. Pio, et al. 2013. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC. Int. J. Cancer 132:1986–1989.
21. Shimada, K., T. Ishikawa, F. Nakamura, D. Shimizu, T. Chishima, Y. Ichikawa, et al. 2014. Collapsin response mediator protein 2 is involved in regulating breast cancer progression. Breast Cancer. 21:715–723.
22. Yu, Z., T. J. Kryzer, G. E. Griesmann, K. Kim, E. E. Benarroch, and V. A. Lennon. 2001. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmune. Ann. Neurol. 49:146–154.
23. Lindner, D. J., E. C. Borden, and D. V. Kalvakolanu. 1997. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin. Cancer Res. 3:931–937.
24. Wang, L., X. Y. Li, G. F. Jiang, J. Z. Liang, Y. Sun, and W. Liu. 2013. Reversal effect of BM-cyclin 1 on multidrug resistance by down-regulating MRP2 in BALB/C nude mice bearing C-A120 cells. J Huazhong Univ Sci Technolog Med Sci. 33:840–844.
25. Koshkina, N. V., C. Khanna, A. Mendoza, H. Guan, L. DeLauter, and E. S. Kleinerman. 2007. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol. Cancer Res. 5:991–999.
26. Liao, D., L. Zhong, T. Duan, R. H. Zhang, X. Wang, G. Wang, et al. 2015. Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-kappaB Pathway. Clin. Cancer Res. 21:5349–5359.
27. Marina, N., M. Gebhardt, L. Teot, and R. Gorlick. 2004. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441.
28. Meyers, P. A., and R. Gorlick. 1997. Osteosarcoma. Pediatr. Clin. North Am. 44:973–989.
29. Brot, S., V. Rogemond, V. Perrot, N. Cholmamloutri, C. Auger, J. Honnaorat, et al. 2010. CRMP-5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP-2. J. Neurosci. 30:10659–10664.
30. Machesky, L. M. 2008. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 582:2102–2111.
31. Shih, J. Y., Y. C. Lee, S. C. Yang, T. M. Hong, C. Y. Huang, and P. C. Yang. 2003. Collapsin response mediator protein-1: a novel invasion-suppressor gene. Clin. Exp. Metastasis 20:69–76.
32. Wu, C. C., J. C. Lin, S. C. Yang, C. W. Lin, J. J. Chen, J. Y. Shih, et al. 2008. Modulation of the expression of the invasion-suppressor CRMP-1 by cycloxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBPalpha. Mol. Cancer Ther. 7:1365–1375.
33. Pan, S. H., Y. C. Chao, H. Y. Chen, P. F. Hung, P. Y. Lin, C. W. Lin, et al. 2010. Long form collapsin response mediator protein-1 (LCRMP-1) expression is associated with clinical outcome and lymph node metastasis in non-small cell lung cancer patients. Lung Cancer 67:93–100.
34. Wang, W. L., T. M. Hong, Y. L. Chang, C. T. Wu, S. H. Pan, and P. C. Yang. 2012. Phosphorylation of LCRMP-1 by GSK3beta promotes filopoda formation, migration and invasion abilities in lung cancer cells. PLoS ONE 7:e31689.
35. Wu, C. C., H. C. Shen, S. J. Chen, H. P. Liu, Y. Y. Hsieh, C. J. Yu, et al. 2008. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8:316–332.
36. Morgan-Fisher, M., J. R. Coughman, and A. Yoneda. 2013. Phosphorylation and mRNA splicing of collapsin response mediator protein-2 determine inhibition of rho-associated protein kinase (ROCK) II function in carcinoma cell migration and invasion. J. Biol. Chem. 288:31229–31240.
37. Vincent, E. E., D. J. Elder, L. O’Flaherty, O. E. Pardo, P. Dzien, L. Phillips, et al. 2014. Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation. PLoS ONE 9:e114725.
38. Sheorajpanday, R., H. Slabbynck, W. Van De Sompel, D. Galdermans, I. Neetens, and P. P. De Deyn. 2006. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP)-5 paraneoplastic optic neuropathy. J. Neuroophthalmol. 26:168–172.
39. Margolin, E., A. Flint, and J. D. Trobe. 2008. High-titer collapsin response-mediating protein-associated (CRMP-5) paraneoplastic optic neuropathy and Vitritis as the only clinical manifestations in a patient with small cell lung carcinoma. J. Neuroophthalmol. 28:17–22.
40. Patel, S., G. Sumitra, B. C. Koner, and A. Saxena. 2011. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin. Biochem. 44:869–872.
41. Yoshimura, T., Y. Kawano, N. Arimura, S. Kawabata, A. Kikuchi, and K. Kaibuchi. 2005. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120:137–149.
42. Brown, M., T. Jacobs, B. Eickholt, G. Ferrari, M. Teo, C. Monfries, et al. 2004. Lpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J. Neurosci. 24:8994–9004.
43. Arimura, N., N. Inagaki, K. Chihara, C. Menager, N. Nakamura, M. Amano, et al. 2000. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J. Biol. Chem. 275:23973–23980.